Physician profile
Daniel Wayne Halayko
NPI 1063831873
$3,418.61
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $534 · 2021: $37.58 · 2022: $1,296 · 2023: $159 · 2024: $38.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supreme Orthopedic Systems, LLC | $2,992.05 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $81.47 | 2021-2024 | Jublia |
| Horizon Therapeutics Plc | $79.93 | 2019-2022 | |
| Sebela Pharmaceuticals INC. | $76.39 | 2020-2023 | Naftin |
| Next Science LLC | $39.92 | 2023 | Blastx, Xperience, Surgx |
| Smith+Nephew, INC. | $38.87 | 2019-2020 | |
| Nevro Corp. | $29.30 | 2023-2024 | Senza |
| Abbvie INC. | $24.58 | 2023 | |
| Ibsa Pharma INC. | $20.04 | 2023 | Tirosint, Licart |
| Paratek Pharmaceuticals, INC. | $18.92 | 2022 | |
| Cashflow Solutions, LLC | $17.14 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Halayko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.